Targeting cyclooxygenase-2 in hematological malignancies: explanation and promise.

Curr Pharm Des. 2008;14(21):2051-60

Authors: physiologist MP, Bancos S, Sime PJ, Phipps RP

There is much welfare in the possibleness ingest of Cox-2 selective inhibitors in compounding with another cancer therapeutics. Malignancies of hemopoietic and non-hematopoietic lineage ofttimes hit accumulated countenance of cyclooxygenase-2 (Cox-2), a key modulator of inflammation. For example, hematological malignancies much as habitual lymphocytic leukemia, habitual myeloid leukemia, Hodgkin’s lymphoma, non-Hodgkin’s lymphoma and binary myeloma ofttimes highly impart Cox-2, which correlates with slummy enduring prognosis. Expression of Cox-2 enhances activity and proliferation of cancerous cells, patch negatively influencing anti-tumor immunity. Hematological malignancies expressing elevated levels of Cox-2 potentially refrain insusceptible responses by producing factors that compound angiogenesis and metastasis. Cellular insusceptible responses thermostated by uncolored dolphin cells, cytotoxic T lymphocytes, and T restrictive cells are also influenced by Cox-2 expression. Therefore, Cox-2 selective inhibitors hit auspicious therapeutic possibleness in patients pain from destined hematological malignancies.

PMID: 18691115 [PubMed - in process]

(Source: Current Pharmaceutical Design)

Tags: Cancer, Cox, Current, Expression, Genes, leukemia, NCR